Correlation between telomere length and efficacy of oral and long-acting injectable antipsychotics on severity and cognitive impairment of schizophrenia

Author(s):  
Nisha Pippal ◽  
Sumita Halder ◽  
Shruti Srivastava ◽  
Rajarshi Kar ◽  
Rachna Gupta ◽  
...  
Cortex ◽  
2020 ◽  
Vol 132 ◽  
pp. 29-40
Author(s):  
Junhong Yu ◽  
Madhu Mathi Kanchi ◽  
Iris Rawtaer ◽  
Lei Feng ◽  
Alan Prem Kumar ◽  
...  

2020 ◽  
Vol 26 (9) ◽  
pp. 906-917
Author(s):  
Adiba Ashrafi ◽  
Stephanie Cosentino ◽  
Min S. Kang ◽  
Joseph H. Lee ◽  
Nicole Schupf ◽  
...  

AbstractObjective:Leukocyte telomere length (LTL) is a widely hypothesized biomarker of biological aging. Persons with shorter LTL may have a greater likelihood of developing dementia. We investigate whether LTL is associated with cognitive function, differently for individuals without cognitive impairment versus individuals with dementia or incipient dementia.Method:Enrolled subjects belong to the Long Life Family Study (LLFS), a multi-generational cohort study, where enrollment was predicated upon exceptional family longevity. Included subjects had valid cognitive and telomere data at baseline. Exclusion criteria were age ≤ 60 years, outlying LTL, and missing sociodemographic/clinical information. Analyses were performed using linear regression with generalized estimating equations, adjusting for sex, age, education, country, generation, and lymphocyte percentage.Results:Older age and male gender were associated with shorter LTL, and LTL was significantly longer in family members than spouse controls (p < 0.005). LTL was not associated with working or episodic memory, semantic processing, and information processing speed for 1613 cognitively unimpaired individuals as well as 597 individuals with dementia or incipient dementia (p < 0.005), who scored significantly lower on all cognitive domains (p < 0.005).Conclusions:Within this unique LLFS cohort, a group of families assembled on the basis of exceptional survival, LTL is unrelated to cognitive ability for individuals with and without cognitive impairment. LTL does not change in the context of degenerative disease for these individuals who are biologically younger than the general population.


2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S490-S490
Author(s):  
Boye FANG ◽  
Elsie Yan ◽  
Keith Tung ◽  
Gengzhen Chen

Abstract Objectives: Elder abuse is a stressful event that can lead to compromised psychological and physical health consequences. This study examines the association between elder abuse and telomere length (TL), a biomarker reflecting cellular aging and disease pathogenesis. Methods: Between 2015 and 2016, 1,002 older adults (aged≥55 years) with cognitive impairment were consecutively recruited from the geriatric and neurological departments of three Grade-A hospitals in Guangdong Province of People’s Republic of China. At two-year follow-up, 958 of these participants were reassessed and 600 of them were randomly selected for this study. The outcome variable is TL (measured in blood cells using a multiplex quantitative polymerase chain reaction) and the major independent variables were current experience of overall abuse, psychological abuse, physical abuse, caregiver neglect, and previous experience of domestic abuse in the past two years. Potential confounding variables include demographic variables and increased severity of cognitive impairment, neuropsychiatric symptoms, sleep disorders, and depressive symptoms. Results: Multivariate regression models show that current experience of overall domestic abuse (t= -5.116, β= -0.376, confidence interval[CI] -20.231–-9.006), psychological abuse (t= -4.431, β= -0.231, [CI] -13.023–-5.023), physical abuse (t= -2.474, β= -0.151, CI -14.116–-1.621), and caregiver neglect were associated with shorter TL (t= -4.470, β= -0.185, CI -10.457–-4.072). Other predictors of shorter TL were previous experience of domestic abuse and increased severity of depression. Discussion: Both current and previous experiences of elder abuse are associated with shorter TL. Multidisciplinary efforts were needed to prevent and intervene elder abuse.


Author(s):  
Elena Bellotti ◽  
Gabriella Contarini ◽  
Federica Geraci ◽  
Sebastiano Alfio Torrisi ◽  
Cateno Piazza ◽  
...  

AbstractSchizophrenia is a disorder characterized by cognitive impairment and psychotic symptoms that fluctuate over time and can only be mitigated with the chronic administration of antipsychotics. Here, we propose biodegradable microPlates made of PLGA for the sustained release of risperidone over several weeks. Two microPlate configurations – short: 20 × 20 × 10 μm; tall: 20 × 20 × 20 μm – are engineered and compared to conventional ~ 10 μm PLGA microspheres in terms of risperidone loading and release. Tall microPlates realize the slowest release documenting a 35% risperidone delivery at 100 days with a residual rate of 30 ng/ml. Short microPlates and microspheres present similar release profiles with over 50% of the loaded risperidone delivered within the first 40 days. Then, the therapeutic efficacy of one single intraperitoneal injection of risperidone microPlates is compared to the daily administration of free risperidone in heterozygous knockout mice for dysbindin-1, a clinically relevant mouse model of cognitive and psychiatric liability. In temporal order object recognition tasks, mice treated with risperidone microPlates outperform those receiving free risperidone up to 2, 4, 8, and 12 weeks of observation. This suggests that the sustained release of antipsychotics from one-time microPlate deposition can rescue cognitive impairment in dysbindin mice for up to several weeks. Overall, these results demonstrate that risperidone-loaded microPlates are a promising platform for improving cognitive symptoms associated to schizophrenia. Moreover, the long-term efficacy with one single administration could be of clinical relevance in terms of patient’s compliance and adherence to the treatment regimen. Graphical abstract Single injection of long-acting risperidone-loaded µPL ameliorates the dysbindin-induced deficit in a clinically relevant mouse model of cognitive and psychiatric liability for up to 12 weeks


2010 ◽  
Vol 299 (1-2) ◽  
pp. 108-111 ◽  
Author(s):  
Dina Zekry ◽  
François R. Herrmann ◽  
Irmgard Irminger-Finger ◽  
Cristophe Graf ◽  
Chantal Genet ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Huijin Lau ◽  
Arimi Fitri Mat Ludin ◽  
Nor Fadilah Rajab ◽  
Suzana Shahar

The increase of ageing population has raised public attention on the concept of successful ageing. Studies have shown that vitamin D, telomere length, and brain-derived neurotrophic factor (BDNF) have been associated with cognitive function. Therefore, this study aimed to identify neuroprotective factors for cognitive decline in different ageing groups. A total of 300 older adults aged 60 years and above were recruited in this population based cross-sectional study. Participants were categorized into three groups: mild cognitive impairment (MCI) (n=100), usual ageing (UA) (n=100), and successful ageing (SA) (n=100). Dietary vitamin D intake was assessed through Diet History Questionnaire (DHQ). Out of the 300 participants, only 150 were subjected to fasting blood sample collection. These samples were used for serum vitamin D and plasma BDNF measurements. Whole blood telomere length was measured using RT-PCR method. The results show that the reduction of the risk of MCI was achieved by higher serum vitamin D level (OR: 0.96, 95% CI: 0.92–0.99, p<0.05), higher plasma BDNF level (OR: 0.51, 95% CI: 0.30–0.88,  p<0.05), and longer telomere (OR: 0.97, 95% CI: 0.95–0.99,  p<0.001). In conclusion, participants with higher vitamin D level, higher BDNF level, and longer telomere length were more likely to age successfully.


Sign in / Sign up

Export Citation Format

Share Document